Frazier Healthcare Partners has named Vivek Sharma and Girish Venkatachaliah to its growth buyout team. Sharma is a former operating partner at Thomas H Lee Partners while Venkatachaliah is the executive vice president and chief technology officer at Decision Resources Group.
SEATTLE–(BUSINESS WIRE)–Frazier Healthcare Partners is excited to announce that Vivek Sharma and Girish Venkatachaliah are joining the firm’s Growth Buyout team to develop investment strategies around healthcare data and AI applications. Vivek joins Frazier as Partner, Data & Analytics Investment Strategies and will devote his time to the sourcing, diligence and leadership of market-shaping commercialization companies serving the pharmaceutical sector with a strong focus on data and analytics. Vivek will also serve in key board and advisor roles that leverage his broader pharma services experience. Girish will work alongside Vivek as Partner, Data & Artificial Intelligence, devoting his time to investments in this new vertical while also developing and implementing data and AI initiatives across the Frazier portfolio.
Vivek brings over 25 years of experience in various leadership roles, as both an executive leader at global healthcare companies as well as an Operating Partner at private equity firm Thomas H Lee Partners. Most recently Vivek served as CEO of Decision Resources Group, a global AI-enabled SaaS platform serving premier pharmaceutical companies, where he achieved significant growth in revenue and margin expansion culminating with the company’s sale in February 2020.
Prior to Decision Resources Group, Vivek served as CEO of Piramal Pharma Solutions and as CEO of Piramal Critical Care, where he was instrumental in significant value creation through his customer focused strategy. Vivek has also served on a number of boards at private companies and is actively involved in several philanthropic institutions.
Girish has over 20 years of experience in technology, data analytics and healthcare roles as both an executive leader and across multiple board and advisor positions. Most recently, Girish served as the EVP and Chief Technology Officer at Decision Resources Group, where he was responsible for products and operations and was instrumental in transforming the company’s AI-enabled SaaS model that generated outsized value upon its sale. Prior to DRG, Girish held VP positions at premier data and analytics companies including athenahealth and IBM, where he was responsible for data and AI strategy, product creation and building functional-area expert teams.
Frazier is excited to partner with these outstanding executives during a pivotal moment at the intersection of technology and healthcare. Stakeholders across the industry have seen meaningful gains from improved technology and data strategies, including hospitals using connected devices, pharma exploring digital trials and algorithm-based drug discovery and payors analyzing population health metrics to shift care from acute to preventative. Companies that are able to harness data to improve their own offering or provide services that help others do so, will be well positioned for the coming decade.
“We are thrilled that Vivek and Girish have chosen to join Frazier as the firm looks to be a leader in driving value through healthcare data and AI applications. Their experience in the healthcare industry, proven leadership experience, and incredible track records will greatly enhance our investing efforts in the sector and our portfolio companies’ ability to harness their data assets,” said Frazier General Partner, Nathan Every.
About Frazier Healthcare Partners:
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion in total capital raised, Frazier has invested in more than 170 companies with investments ranging from company creation and venture capital to buyouts of profitable middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical outsourced services, healthcare technology, provider practices and other related sectors. The Life Sciences team invests primarily in novel therapeutics that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada and Europe.
For more information about Frazier Healthcare Partners, visit www.frazierhealthcare.com.